Different alterations (i.e., single pint mutations, splicing variants, fusion proteins) can potentially represent useful markers for the diagnosis of specific tumors, in some cases even targetable with selective drugs, as in the case of enzastaurin, employed to treat melanoma and characterized by the presence of spliced PKCβ isoforms. The gene discussed is PRKCB; the disease is melanoma.